RxDoctor Payments Data

Gaileen Doxsie

Gerontology · West Chester, OHNPI 1972500023

Payments from drug & device makers

$1,578in general payments, 2019–2025

Across 29 payments — averaging $54.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$897
  • AbbVie$277
  • Novo Nordisk$230
  • Lilly USA, LLC$57
  • Exact Sciences$41
  • Pfizer$38
  • plus $38 from 1 others

What the payments were for

  • Food & beverage$1,578100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca10$897
AbbVie4$277
Novo Nordisk6$230
Lilly USA, LLC3$57
Exact Sciences2$41
Pfizer2$38
Merck2$38

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,578 in reported general payments places this provider in the 80th percentile of 361 gerontology providers in Ohio.

See all gerontology providers in Ohio

Medicare billing

Part B allowed, 2024
$36,117
Medicare patients
146
Services billed
625

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine21$147,717
OzempicSemaglutide26$37,070
EliquisApixaban47$35,295
XareltoRivaroxaban23$23,640
RexultiBrexpiprazole12$17,875
JanuviaSitagliptin Phosphate23$14,930
TrulicityDulaglutide12$9,791
Incruse ElliptaUmeclidinium Bromide27$9,249
MyrbetriqMirabegron17$5,015
Estradiol27$2,732
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$2,325
Albuterol Sulfate HfaAlbuterol Sulfate92$2,239
Atorvastatin Calcium238$1,703
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$1,643
Gabapentin64$1,321

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$230$37,07026 claims
PfizerEliquis$38$35,29547 claims
MerckJanuvia$38$14,93023 claims
Lilly USA, LLCTrulicity$57$9,79112 claims
AbbVieSynthroid$277$1,27117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 361 gerontology providers in Ohio.

Other gerontology in West Chester

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →